Beam Therapeutics Inc.
General ticker "BEAM" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.8B (TTM average)
Beam Therapeutics Inc. follows the US Stock Market performance with the rate: 31.0%.
Estimated limits based on current volatility of 5.1%: low 24.84$, high 27.51$
Factors to consider:
- Total employees count: 507 as of 2022
- Top business risk factors: Insufficient funding, Market competition, Strategic risks and growth management, Regulatory and compliance, Labor/talent shortage/retention
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [14.44$, 34.03$]
- 2025-12-31 to 2026-12-31 estimated range: [11.30$, 27.61$]
Financial Metrics affecting the BEAM estimates:
- Negative: with PPE of -5.9 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -15.49 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Inventory ratio change, % of -47.76 <= -0.75
- Positive: Shareholder equity ratio, % of 66.45 > 63.39
- Positive: Investing cash flow per share per price, % of 8.25 > -0.66
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term BEAM quotes
Long-term BEAM plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $60.92MM | $377.71MM | $63.52MM |
| Operating Expenses | $399.40MM | $554.19MM | $479.09MM |
| Operating Income | $-338.48MM | $-176.49MM | $-415.57MM |
| Non-Operating Income | $78.30MM | $45.32MM | $38.87MM |
| R&D Expense | $311.59MM | $437.38MM | $367.56MM |
| Income(Loss) | $-260.18MM | $-131.16MM | $-376.70MM |
| Taxes | $3.41MM | $1.37MM | $0.04MM |
| Other Income(Loss) | $-25.50MM | $0.00MM | $0.00MM |
| Profit(Loss)* | $-289.09MM | $-132.53MM | $-376.74MM |
| Stockholders Equity | $733.47MM | $981.33MM | $733.54MM |
| Assets | $1,341.71MM | $1,459.71MM | $1,103.82MM |
| Operating Cash Flow | $22.53MM | $-149.19MM | $-347.25MM |
| Capital expenditure | $48.95MM | $33.73MM | $8.95MM |
| Investing Cash Flow | $-461.34MM | $71.84MM | $185.01MM |
| Financing Cash Flow | $111.59MM | $276.45MM | $7.74MM |
| Earnings Per Share** | $-4.13 | $-1.72 | $-4.58 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.